Member Info for Jimzi

An entrepreneur accused of scamming investors for millions of dollars with a bogus blood test has surprised a US court by testifying in her defence.

Elizabeth Holmes is accused of making false claims about her firm Theranos, including that its technology could detect diseases with a drop of blood.

Ms Holmes, 37, faces multiple charges of fraud and could spend years in jail if found guilty. She denies wrongdoing.

At its peak her firm was valued at $9bn (£6.5bn).

As usual - over complicated.
You ratify a completed signed contract.
But about to be ratified, the contract changes [for more services!!]
Pretty certain we have been here before.

Sign the contract and then sign additional contracts as and when. [as this way you know you are not being led up the garden path]

At least Imutex is still around after years of silence.

Pretty certain we got P1 3 years ago so its a bit sad it takes this long to showcase it - Flu-v inaction continues. That's the main reason for me holding so I am Imutex disappointed overall.

that you get the heads up to an imminent liquidity event where you can work out what the price won't be - £27m! and roughly what it could be.

Zzzz. DSMR into basic reporting

with this volume, time passage and silly spread -[ 24.6 v 25.3 for one share!!]I think we can now safely conclude that Cannacord have not and are not selling a bean.- 13% sticky.

I understood our underlying investments were good so why is the share price not living up to it...?

Because if we had perfect markets, the price would move in an instant on accurate news .

Otherwise, it’s fear, greed, waiting, under researching, trading, etc

https://www.benzinga.com/general/biotech/21/11/24034789/this-company-says-its-one-step-closer-to-transforming-cancer-treatment-with-its-latest-groundbrea&ved=2ahUKEwiIvOjAmJH0AhWrg-AKHQl9C6kQxfQBKAB6BAgPEAI&usg=AOvVaw1N4Syv3de0jYbCf-4lFcLm

Let’s look at $PDSB Think about the company's current programs in relation to valuation; Universal flu, NCI trial and Tarp. Only one of those gets us today’s market cap. Mix in transformational Keydtruda, which has a good chance & we have ourselves a blockbuster

https://www.proactiveinvestors.co.uk/companies/news/965804/netscientific-plc-new-business-model-delivering-returns-965804.html/long

At last a research note that has picked up on the enormous potential of Glycotest. - $800m per year market alone in US., China royalties 6% on sales etc, but even this just skims the surface. [I will post more later]

The other piece from yesterday had two good snippets:

1] However, whilst that appears to be exciting and potentially lucrative for the future and where news on that front should not too far away, the CEO says that the link with Astra Zeneca is also very exciting, as there are a number of other companies within the NSCI portfolio that fit with the focus of Astra and other UK Pharmaceutical companies on diagnostics, oncology, regenerative medicine and other areas.

2] But, within the Martlet deal though, there is, he says, a bonus, in that some of the investments being acquired are now very mature which creates a good climate in terms of exits.

Great interview - concise, direct and serious - given his track record, this is the sort of elder statesman who can deliver - old school no nonsense boys - not your modern gobby wideboys!

This should get more sells than Older's post lol

Mr 10k and 5k have been with us for years - go back and you can see they buy them back then sell them etc etc . Whatever floats your boat

Way, what gains with those choices. ? One complete basket and the other a lottery ticket- joke
And telling us your fictitious stop loss. Get a life man .

Know about the companies with world leading (IPR protected) in respiratory and liver diagnostics , oncology, antigen plus 5G and satellite 60% power reduction plus as a Bruce bonus, a couple company that can slash the NHS GHG running at 4% of national levels.

I’m sure this is all gobblegook to many. That’s why dyor sometimes makes you rich.

Oh, forget the other 10-50 investments.

Too many peeps want instant news and gratification- buy and hold and there will be a groundswell of incremental gratification if you have the attention span greater than a gnat
And a bag with 21m is easy.

GL

I meant the base price in a few days - i.e the placing price being the bottom.
Y/E is anyone's guess

Sort of - 3.4% holder wet his pants at the enrollment halt - totally unrelated to PDS - its was FDA procedure change - and dumped - which with only 1m shares = drop plus advfn traders winding each other up over nonsense and charts.
Apart from DYOR, take comfort from
1]W H Ireland target now £1.80
2]Investors Chronicle repeated target £1.90 and thats just book value so does not take into account any analysis of the holdings
Cannacord took 10% of the company in June at £1.3 - placing done in a day!

Well no TR from Canna [ which there won't be - they report the day after threshold sale]
So the free float is stickier than many thought.
This will re-rate to 30p at some point

Who would want to be in a climate change stock atm

From the Lancet

Anaesthetic gases represent 5% of the carbon footprint for all acute National Health Service (NHS) organisations, or 50% of gas emissions from the heating of acute NHS buildings and water.
Therefore, agreeing a standardised approach towards the limitation of harm caused by anaesthetic gases presents obvious problems, since the scope must involve everyone, everywhere.
FS is an unpaid member of Airedale ecoawAire, Bradford Sustainable Health Economy, the National Health Service (NHS) Sustainable Development Unit (Northern Region Group), and the Environmental Task Force of the Association of Anaesthetists of Great Britain and Ireland, working to reduce the environmental effect of health care. He has received travel funding from the NHS Sustainable Development Unit on several occasions and he is a Clinical Advisor to SageTech Medical, a company trying to improve techniques for scavenging of anaesthetic vapours.

https://www.thelancet.com/journals/lanplh/article/PIIS2542-5196(17)30040-2/fulltext

For PDSB, cancer vaccine has a much bigger market in addition to immunotherapy . That is cancer prevention. All the cancer survivors would like to take a vaccine if clinical trial shows it could reduce cancer relapse in next 10 years, even 30% reduction.
https://twitter.com/search?q=%24PDSB&src=recent_search_click&f=live